header logo image


Page 571«..1020..570571572573..580590..»

Passing the test of time to build businesses that last – YourStory

May 2nd, 2020 7:49 pm

April 1, 2020. On this day, most of the world was battling to defeat a virus that has wreaked havoc, created chaos, and upended normality as we know it.

Meanwhile, on the same day, Fauja Singh quietly celebrated his 109th birthday in the UK. Born in 1911, Fauja Singh has lived through two World Wars, the Great Depression, the Indian fight for independence, and the Cold War. In 2004, Fauja Singh was chosen as the face of Adidas, replacing David Beckham.

Born in Punjab, Fauja is the worlds oldest marathoner. At the age of 92, Singh ran a marathon in 5 hours 40 minutes, having taken up running only when he was 89. In 2011, Fauja Singh became the first 100-year-old to complete a marathon. Even now, Fauja says he walks at least 5 miles a day after a hernia finally put a stop to his marathon running.

Last year, in a different sport, Serena Williams became the oldest Grand Slam finalist in Open Era tennis history. At 37 years 291 days, Williams joined the 37-year-old Roger Federer in the Wimbledon finals. All three of Federers last Grand Slam trophies have come after the age of 35. Closer home, Sachin Tendulkar was 40 when he played his last Test innings of 74 against the West Indies in 2013.

Sports can offer parallels to situations that we face in our personal and professional lives. Thinking of the longevity of some of the worlds most remarkable athletes during these times made me think of the longevity of businesses too, especially during a crisis.

Sportspersons like Serena and Federer have shown remarkable endurance in staying at the top for decades in a highly competitive sport. Athletes like them are built to last. But its not just talent that has made them last these years.

Their fitness is not mere genetics, even though their skills are unique. Hours of hard work, relentless hours of practice, and a constant desire to hone their skills have made them endure the best of times and the worst of times.

Founded in 578 AD, Kongo Gumi in Osaka, Japan, is the oldest continually operating company in the world. This construction company specializes in building Buddhist temples. I hadnt thought a company could be that old! Companies such as Bofors and Saint Gobain were established in the 16th century, and as I scrolled down that list, I came across increasingly familiar names.

In India, companies such as the Wadia Group, State Bank of India, the Tata Group, Aditya Birla Group, Shalimar Paints, and more have been around for more than 100-300 years.

They were there before the internet, air travel, automobiles, and before televisions. And they are still here now in the times of Snapchat, Facebook, supersonic jumbo jets, luxury cars, and smart TVs.

These are not companies that have barely made it. No. Some of them are giant companies that have constantly reinvented themselves and remained at the forefront of innovation. They have adapted to every situation possible to stay current. They have survived wars, depression, plague, booms, busts, rebellions, revolutions, political upheavals, and more in the process.

Clearly, theres something we can learn from companies that were built to last. Take GE, for example. The company is the only one still listed in the Dow Jones Industrial Index from 1896. Its power to endure comes from its range. Throughout its history, GE has constantly added and exited different business segments. This diversification and divestiture have helped the company stay afloat despite constant market and business fluctuations.

When you look at the list of the worlds longest-surviving companies, you will find that they have strong guiding principles that quickly become living history in these companies. Their purpose and values are defined by those principles. They are led by the right strategic vision and adherence to fundamental values through the ages.

The key values that stand out for me from these companies are: heritage, value, flexibility, and adaptation.

So, how do you build a startup that will last? All long-lasting companies had strong founders who made building the company their life mission. Over time, they created strong organisational structures and built their philosophy into the foundations of the business.

Founders need to dream of growing their companies beyond the startup phase.

Building companies that last requires creating operating guidelines in mind:

Leverage cash flow: The oldest-surviving companies all understood the importance of money in an old-fashioned way. They knew how useful it is to have spare cash all the time. Crucially, they pursued growth within their means, practicing fiscal discipline.

It may seem like empty advice, but startups, I believe, should always be thinking about cash flow.

Cash is important to come out of any crisis stronger and thriving.

Invest in innovation: Long-lasting companies also focus on pragmatic innovation. They are paranoid about innovation. They have taken capital-efficient, well-thought-out risks to drive innovation consistently and creatively.

Indias digital revolution has been led by a dramatic rise in innovation. The ArogyaSetu app is a wonderful example of pragmatic innovation with more than five crore downloads just 13 days after its launch. Without an internal commitment to innovation, I believe that even the strongest brands in the fastest-growing industries will eventually face immense difficulties and wither.

Adapt to the times: Learning from the worlds longest-surviving companies shows that they changed with the times. They remained aware of the environment around them, and embraced change, instead of opposing it.

Barclays, for example, started off in the 16th century as goldsmith bankers. But its the same brand that launched the UKs first debit card and introduced the worlds first ATM in 1969. Quite a change from being goldsmith bankers!

Kongo Gumi, as I wrote earlier, specialised in building Buddhist temples. But during World War II, when funds were low, the company switched to making coffins to survive.

Whenever there is new customer behavior, there is an opportunity to think about doing your business differently.

Twinings, which has been around for 300 years, produced such high-quality tea that Queen Victoria gave the company a Royal Warrant for tea in 1837.

Long-standing companies focus on building long-lasting relationships with customers and partners.

A startup needs to focus on delighting customers - client satisfaction cant be lost while scaling.

Building strong processes means your business is protected from any eventualities, like a drastic drop in revenue as triggered by the current pandemic or even the exit of a key member of the top management.

And we can move through these extraordinary times, too, when we learn, adapt, and embrace this change. For that, we have the timeless weight of history to guide us.

(Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the views of YourStory.)

How has the coronavirus outbreak disrupted your life? And how are you dealing with it? Write to us or send us a video with subject line 'Coronavirus Disruption' to editorial@yourstory.com

Read the rest here:
Passing the test of time to build businesses that last - YourStory

Read More...

Global Precision Medicine Software Market Growth and Forecast Research 2020-2027 Cole Reports – Cole of Duty

May 2nd, 2020 7:48 pm

Globalmarketers.biz recently added a detailed research study focused on the Global Precision Medicine Software Market across the global, regional and country level. The report provides 360 analysis of Market from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Precision Medicine Software market and estimates the future trend of industry on the basis of this detailed study.

Request a sample Report :https://www.globalmarketers.biz/report/others/2015-2027-global-precision-medicine-software-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146709#request_sample

The Major Players are:

Abbott Laboratories(US)Syapse, Inc. (US)Roper Technologies(US)Sunquest Information Systems Inc. (US)Pfizer, Inc., Merck & Co., Inc.(US)N-of-One, Inc. (US)NantHealth, Inc. (US)LifeOmic Health, LLC (US)Fabric Genomics (US)Allscripts(US)GlaxoSmithKline plc(UK)Gene42, Inc. (Canada)Foundation Medicine, Inc. (US)Koninklijke Philips N.V. (Netherlands)PierianDx, Inc. (US)Translational Software, Inc. (US)Flatiron Health, Inc. (US)IBM Watson Group (US)Sanofi S.A.(France)Tempus Labs, Inc. (US)AstraZeneca plc(US)2bPrecise LLC (Israel)Qiagen(Germany)SOPHiA GENETICS SA (Switzerland)Human Longevity, Inc. (US)

The latest research study on the Precision Medicine Software market is a pivotal collection of insights pertaining to this industry vertical, with respect to certain parameters. The research report focuses on providing an in-depth synopsis of this industry, specifically illuminating the market industry size and share, application bifurcation, product types, as well as novel opportunities in the business space.

Segmentation Overview:

Product Type Segmentation :

Cloud-basedOn-premise

Application Segmentation :

Healthcare providersResearch centers & Government institutesPharmaceutical & Biotechnology companiesOther end users

Make an Inquiry About This Report @ https://www.globalmarketers.biz/report/others/2015-2027-global-precision-medicine-software-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146709#inquiry_before_buying

Driving Forces as well as Challenges of the Precision Medicine Software market: How does the study elaborate on the same?

The report entails the various drivers and restraints impacting the commercialization landscape of the Precision Medicine Software market.

The Precision Medicine Software market research report illustrates details about the myriad challenges which this industry presents. Also, the impact that these challenges may have on the overall industry trends.

Significant details revealed in the report also fall along the likes of market concentration ratio over the forecast years.

Ask for Discount on Precision Medicine Software Market Report at:https://www.globalmarketers.biz/discount_inquiry/discount/146709

The geographical spectrum of the business as well as its influence on the overall Precision Medicine Software market outlook:

With respect to the regional frame of reference, the report segments the Precision Medicine Software market into USA, Europe, Japan, China, India, South East Asia.

Pivotal insights about the product consumption across numerous regions are provided. The revenue recorded by these topographies have been included in the study.

The study explains details about the consumption market share spanning the numerous geographies. It is also inclusive of the market share that these regions accrue over the forecast period, as well as the product consumption growth rate.

For More Details On this Report:

Some of the Major Highlights of TOC covers:

Executive Summary

Global Precision Medicine Software Production Growth Rate Comparison by Types (2015-2027)

Global Precision Medicine Software Consumption Comparison by Applications (2015-2027)

Global Precision Medicine Software Revenue (2015-2027)

Global Precision Medicine Software Production (2015-2027)

North America Precision Medicine Software Status and Prospect (2015-2027)

Europe Precision Medicine Software Status and Prospect (2015-2027)

China Precision Medicine Software Status and Prospect (2015-2027)

Japan Precision Medicine Software Status and Prospect (2015-2027)

Southeast Asia Precision Medicine Software Status and Prospect (2015-2027)

India Precision Medicine Software Status and Prospect (2015-2027)

Check Table of Contents of This Report @ https://www.globalmarketers.biz/report/others/2015-2027-global-precision-medicine-software-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146709#table_of_contents

Manufacturing Cost Structure Analysis

More here:
Global Precision Medicine Software Market Growth and Forecast Research 2020-2027 Cole Reports - Cole of Duty

Read More...

From ‘eating delicious things’ to avoiding marriage, these are the secrets to a long life, according to people who lived beyond 100 – Business Insider…

May 2nd, 2020 7:48 pm

Though improved medical care and knowledge has helped people live longer and healthier lives, there still arent many that live beyond a century. According to a recent study, just 0.0173% of Americans live to 100.

These people from around the world have all lived well beyond that, beating the odds to achieve long lives. Each centenarian or super-centenarian (those who live beyond 110) on our list shared their tips for longevity.

From daily eating habits to exercise routines, these are their tips for a long life.

Misao Okawa was born in 1898 in Japan. Japan has the most centenarians in the world. According to the Japan Times, in 2018, the country had 69,785 people over 100, nearly 90% of whom were women.

In 2014, Guinness World Records recognised Okawa as the worlds oldest living person. She cited eating sushi and getting a good nights sleep as the reasons for her long life.

Morano was born on 29 November, 1899, in the Piedmont region of Italy. She told the BBC that she believed her long life was partly due to genetics, but she also ate a diet of three eggs a day, two of them raw, for more than 90 years.

Morano didnt have an easy life her only son died at just 6 months old, and she had an abusive marriage. She believed leaving her marriage in 1938 contributed to her longevity. She told the New York Times, I didnt want to be dominated by anyone.

Morano was alive in three centuries, and before her death on April 15, 2017, she was believed to be the last living person born in the 19th century.

Weaver was the oldest living person in the United States from her 116th birthday on July 4, 2014, until her death in her home state of Arkansas in April 2015. She was also the worlds oldest living person for less than a week before her death.

She told Time that her secret to long life was kindness, but she also attributed it to not drinking or smoking, and getting plenty of sleep. Additionally, she didnt have any chronic health conditions, a rarity for people of her age.

Gallan was born in Aberdeen, Scotland, in 1906, and died in March, 2015, at age 109.

In an interview with STV News, she said, I also made sure that I got plenty of exercise, ate a nice warm bowl of porridge every morning, and have never gotten married.

Imich was born in Poland on February 4, 1903. He moved to the United States in 1951 after surviving the Holocaust and a Soviet gulag.

He told the New York Times that he believed his long life came down to genetics and exercise. I was a gymnast. Good runner, a good springer. Good javelin, and I was a good swimmer, he said. He also never drank alcohol, which he believed was another contributing factor.

He was given the title of worlds oldest man by Guinness World Records at 111 years old on May 8, 2014, and held the title until his death on June 8, 2014.

Veillard was born on February 28, 1907, in Haiti. He was married in 1932, and he and his wife, Jeanne, moved to the United States in 1968.

USA Today interviewed the Veillards, one of the oldest living couples, in 2015. At the time, Jeanne was almost 105 and Duranord was about to celebrate his 108th birthday.

He told USA today that his secret was waking up early each day to do five to seven push-ups before eating a healthy breakfast of oatmeal and fresh fruit. The couple would also have fish and vegetables for lunch and dinner.

Duranord died at age 111 in June 2018, and Jeanne died just a few months later, in November of that year, at age 108.

Jeralean Talley was born in Montrose, Georgia, in 1899. She moved to Michigan in the 1930s, where she spent the rest of her life until she passed on June 17, 2015.

According to USA Today, Talley was very religious, and her friends and family said she lived by the motto treat people how you want to be treated.

She told Time that her secret to a long life included her devout faith, as well as a diet rich in pork, including pigs feet and ears.

Bernardo LaPallos family believe he was born on August 17, 1901, in Vitoria, Brazil. Both his parents lived long lives his father reached 99 and mother lived to 105. He died on 19 December, 2015, at age 114.

LaPallo was known for his healthy lifestyle books, where he shared how he lived such a long and healthy life.

In an interview with National Geographic, he said, My longevity is due to my obedience and moderation. I have based my life on following what my father told me. He also said eating plenty of fresh fruit and vegetables, going to bed early, and exercising kept him healthy.

He also shared his daily routine: I get up at 3:30 or 4 in the morning, go for my walk, take my shower, rub my body down with olive oil, make my breakfast. Stress is a killer, my daddy told me that. Its important to take time to relax and exercise your brain, such as by doing crossword puzzles.

Jiroemon Kimura was born on April 19, 1897, in Kyoto, Japan. In 2012, at 115, he became the worlds oldest living person and held the title until his death on June 12, 2013.

In an interview with the Guardian, he said his secret to a long life was watching his food portion sizes, waking early in the day, and reading newspapers.

He told Patch a few other ways he kept healthy for so long. Its important to make daily exercise a discipline, he said. He also cited overcoming adversity as something that made him strong. After every storm, peace always comes, he said.

According to his papers and reportedly verified by the Indonesian government, Mbah Gotho was born in December 1870. However, the country only started recording births in 1900, so the topic remains up for debate.

Gotho told the BBC that his long life was due to his loving family. He was a heavy smoker until his death, and outlived four wives, 10 siblings, and all of his children.

Calment is believed to have been born in Arles, France, in 1875. However, some doubt has been cast on this date, as many researchers cite her age at the time of death as statistically impossible. Nevertheless, she remains the official oldest person to have lived.

According to the New Yorker, she smoked for most of her life, only quitting at 117, five years before her death. She also drank a glass of port every night. She also thoroughly enjoyed chocolate. Calment passed on August 4, 1997, of unknown causes.

Jones was born on July 6, 1899, in Lowndes County, Alabama. She was the third of 11 children. She moved to New York in the 1920s, and although she never had any children, she remained very close with her siblings and their children.

According to Insider, at 115, Jones was still eating bacon and grits for breakfast, and she cited bacon as a food that helped her live a long life. She also ate a lot of fruit. Additionally, her niece said that she never drank, partied, or did drugs.

However, more than anything, it was a loving family that kept Jones alive so long, as they cared for her and visited every Sunday.

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.

See more here:
From 'eating delicious things' to avoiding marriage, these are the secrets to a long life, according to people who lived beyond 100 - Business Insider...

Read More...

Dr. David C. Karli’s Opinion on Regenerative Medicine and Age Prevention | – SpaceCoastDaily.com

May 2nd, 2020 7:45 pm

Aging is an inevitable process. We cannot escape or prevent getting older but what if theres a fascinating field of medicine that can manage the aging process and prolong our health and vitality and longevity as we age?

Aging is an inevitable process. We cannot escape or prevent getting older but what if theres a fascinating field of medicine that can manage the aging process and prolong our health and vitality and longevity as we age?

Keeping in mind that there may never be an approach to totally stop or reverse aging, there have been some surprising disclosures to how Regenerative Medicine can naturally heal our body without the use of any surgical procedure.

Rejuvenating Old Cells to Healthy ones

The paces, stresses, and complexities in life drive us to age prematurely thereby breaking down our cells. Cell breakdown may lead to several health conditions like cancer, heart disease, Alzheimers and others.

Driving our bodies to age quickly, cell-breakdown is host to many age-related diseases, causing more than 100,000 deaths per day.

Dr David C Karli is an Ivy-trained physician, specialized in treating athletic injuries by inducing regenerative medicine and stem cell therapy in treatments.

He accepts the fact that patients can increase an additional 30 years of life by using Regenerative Medicine. One such innovation uses stem cells, however, there are issues with these cells.

They may not replace the original, diseased cells rapidly enough, or they may start to replicate uncontrollably, bringing about malignant growth.

Yet, Regenerative Medicine definitely guarantees the complete curing of a wide range of diseases, and ideally, slowing down the aging process too.

Stem Cell Therapy Programs with Promising Results

With solid funding and rapid advancements, one stem cell therapy that promises great outcomes is transfusions. In this therapy, stem cells are extracted from the patient and grown in cell culture to increase the number of cells. Following this, those cells are injected back into the patients body.

Dr. Karlis keen interest in Transfusions led him to create biologic products that can cause an age-related decline in a persons strength, endurance, and various other physical abilities.

At his biotech firm, Greyledge Technologies, biologic products are prepared by processing materials (blood or bone marrow) and implanting them into the human body to replicate the diseased tissues.

With an FDA-registered laboratory environment, the outcomes are promising and are an anti-aging protocol.

Telomeres may be the next-gen solution for Anti Aging

Telomeres are essential parts of our DNA that are connected to the premature aging cells. Situated at the end caps of our DNA strands, the information within Telomeres is lost while DNA replicates to the extent that they stop replicating.

If DNA replicates without losing information, scientists believe that Telomeres can significantly help to slow down the aging process.

Similar is the case with Metformin, a pharmaceutical reagent that improves wound healing. Proven to counteract aging, Metformin is now being tested for its unique ability to mimic calorie restriction.

Anti-Aging Through Regeneration

Utilizing induced tissue regeneration, this technology is a new approach to anti-aging treatment. Combining telomerase therapy and induced tissue regeneration, anti-aging through regeneration includes the study of the impact on age-related diseases like diabetes, metabolic disorders, cardiovascular disease, and others.

This technique focuses on the cells that are generated in our body during youth. As we age, these cells are lost and lead to a metabolic imbalance.

Scientists and Researchers are trying to find a way in which these cells can be restored to reverse the signs of aging and create a balance.

Humans have the ability to regenerate damaged and diseased tissues. However, this only happens during the first few weeks of development. With the help of Artificial Intelligence, scientists are trying to unlock this potential ability in humans.

The Future of Anti-Aging

With several breakthroughs on the horizon, cure-all promises and best outcomes, these anti-aging protocols have a long way to go.

While the introduction of regenerative medicine and stem cell therapies to redefine orthopedic treatment sounds like a miracle, there are still unexplored paths that need to be taken.

With all the benefits regenerative medicine has to offer, there will always be an eye on the never-ending search for the fountain of youth.

CLICK HERE FOR BREVARD COUNTY NEWS

Read the rest here:
Dr. David C. Karli's Opinion on Regenerative Medicine and Age Prevention | - SpaceCoastDaily.com

Read More...

Stem Cell Therapy Shows 83% Survival in COVID-19 Patients Dependent on Ventilator – HospiMedica

May 2nd, 2020 7:45 pm

Ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) who were treated with intravenous infusions of an allogeneic mesenchymal stem cell product candidate had a survival rate of 83%.

The allogeneic mesenchymal stem cell product candidate remestemcel-L from Mesoblast Limited (Melbourne, Australia) was administered within the first five days under emergency compassionate use at New York Citys Mt Sinai hospital during the period March-April 2020. Patients received a variety of experimental agents prior to remestemcel-L. All patients were treated under an emergency Investigational New Drug (IND) application or expanded access protocol at Mt Sinai hospital. 75% of the patents successfully came off ventilator support within a median of 10 days, in contrast to only 9% of ventilator-dependent COVID-19 patients being able to come off ventilators with standard of care treatment and only 12% survival in ventilator-dependent COVID-19 patients at two major referral hospital networks in New York during the same time period. These poor outcomes are consistent with earlier published data from China where mortality rates of over 80% were reported in patients with COVID-19 and moderate/severe ARDS.

The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS, said Mesoblast Chief Executive Dr. Silviu Itescu. We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients.

There is a significant need to improve the dismal survival outcomes in COVID-19 patients who progress to ARDS and require ventilators, said Mesoblast Chief Medical Officer Dr Fred Grossman. We have implemented robust statistical analyses in our Phase 2/3 trial as recommended by the US Food and Drug Administration (FDA) in order to maximize our ability to evaluate whether remestemcel-L provides a survival benefit in moderate/severe COVID-19 ARDS.

Related Links:Mesoblast Limited

View post:
Stem Cell Therapy Shows 83% Survival in COVID-19 Patients Dependent on Ventilator - HospiMedica

Read More...

Stem Cell Therapy Market Growth Opportunities, Challenges, Key Companies, Drivers and Forecast to 2026 Cole Reports – Cole of Duty

May 2nd, 2020 7:45 pm

Allosource

Global Stem Cell Therapy Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. The competitive analysis helps the reader understand the strategies and collaborations that players focus on in order to survive in the market. The reader can identify the players fingerprints by knowing the companys total sales, the companys total price, and its production by company over the 2020-2026 forecast period.

Global Stem Cell Therapy Market: Regional Analysis

The report provides a thorough assessment of the growth and other aspects of the Stem Cell Therapy market in key regions, including the United States, Canada, Italy, Russia, China, Japan, Germany, and the United Kingdom United Kingdom, South Korea, France, Taiwan, Southeast Asia, Mexico, India and Brazil, etc. The main regions covered by the report are North America, Europe, the Asia-Pacific region and Latin America.

The Stem Cell Therapy market report was prepared after various factors determining regional growth, such as the economic, environmental, technological, social and political status of the region concerned, were observed and examined. The analysts examined sales, production, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2020 to 2026. These analyzes help the reader understand the potential value of investments in a particular country / region.

We Offer up to 30% Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=003

Key Benefits for Stakeholders:

The report provides an in-depth analysis of the size of the Stem Cell Therapy world market, as well as recent trends and future estimates, in order to clarify the upcoming investment pockets.

The report provides data on key growth drivers, constraints and opportunities, as well as their impact assessment on the size of the Stem Cell Therapy market.

Porters 5 Strength Rating shows how effective buyers and suppliers are in the industry.

The quantitative analysis of the Stem Cell Therapy world industry from 2020 to 2026 is provided to determine the potential of the Stem Cell Therapy market.

This Stem Cell Therapy Market Report Answers To Your Following Questions:

Who are the main global players in this Stem Cell Therapy market? What is the profile of your company, its product information, its contact details?

What was the status of the global market? What was the capacity, the production value, the cost and the profit of the market?

What are the forecasts of the global industry taking into account the capacity, the production and the value of production? How high is the cost and profit estimate? What will be the market share, supply, and consumption? What about imports and export?

What is market chain analysis by upstream raw materials and downstream industry?

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=003

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis

View post:
Stem Cell Therapy Market Growth Opportunities, Challenges, Key Companies, Drivers and Forecast to 2026 Cole Reports - Cole of Duty

Read More...

Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 – Latest Herald

May 2nd, 2020 7:45 pm

Global Stem Cell Therapy market report presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis and key drivers. The market size of global Stem Cell Therapy market is anticipated to grow at large scale over the forecast period (2020-2025). The main purpose of the study report is to give users an extensive viewpoint of the market. So that users can apply strategic processes to benchmark themselves against rest of the world. Key drivers as well as challenges of the market are discussed in the report. Also reports provides an in depth analysis of the Stem Cell Therapy market with current and future trends.

Get Sample Copy of this Report:https://www.adroitmarketresearch.com/contacts/request-sample/691

In addition, study report offers an array of opportunities for the players participating in the industry. This ultimately leads into the growth of the global Stem Cell Therapy market. Furthermore, report offers a comprehensive study on market size, revenue, sales, growth factors and risks involved in the growth of the market during the forecast period. The factors which are influencing the growth the market are mentioned in the report as well as the challenges which can hamper the growth of the market over the forecast period.

In addition, report presents quantitative as well as qualitative narration of global Stem Cell Therapy market. The research report is beneficial for educators, researchers, strategy managers, academic institutions and analysts. Thus report helps all types of users to identify the strategic initiatives so that they can understand how to expand the global Stem Cell Therapy market business across the globe for the product development. Moreover, research report provides in depth analysis of all the segments which can impact on the market growth.

Browse the complete report @https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

The company profile section also focusses on companies planning expansions along with mergers & acquisitions, new initiatives, R&D updates and financial updates. But, one of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Stem Cell Therapy report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. The companies focused on in this report are pioneers in the Stem Cell Therapy market. Right from history to future plans the report give a detailed roadmap of the industry that the readers can rely on. The uplifting of any region in the global market is dependent upon the market players working in that region.

In the final section of the report on Stem Cell Therapy Market, the dashboard view of the companies is provided, to compare the current industrial scenario and their contribution in total Stem Cell Therapy Market. Moreover, it is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment. Report audiences can gain segment-specific manufacturer insights to identify and evaluate key competitors based on the in-depth assessment of their capabilities and success in the Stem Cell Therapy Marketplace.

For Any Query on the Stem Cell Therapy Market:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more from the original source:
Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Latest Herald

Read More...

COVID-19 Outbreak Bestows Lucrative Opportunities to Rheumatoid Arthritis Stem Cell Therapy Market; Demand to Remain High Post Pandemic – Latest…

May 2nd, 2020 7:45 pm

COVID-19 Analysis on the Global Rheumatoid Arthritis Stem Cell Therapy Market

A recent market research report on the Rheumatoid Arthritis Stem Cell Therapy market published by Fact.MR is an in-depth assessment of the current landscape of the market. Further, the report elaborates on the impact of the COVID-19 on the Rheumatoid Arthritis Stem Cell Therapy market and provides a thorough understanding of the growth potential of each market segment over the forecast period (2020-2030).

According to the analyst at Fact.MR, the Rheumatoid Arthritis Stem Cell Therapy market is evenly slated to register a CAGR growth of ~XX% during the assessment period and attain a value of ~US$ XX by the end of 2030. The report analyzes the micro and macro-economic factors that are projected to impact the growth of the Rheumatoid Arthritis Stem Cell Therapy market in the upcoming years. Further, a detailed analysis of the business continuity strategies of leading market participants is enclosed in the presented report.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Key Insights Enclosed in the Report

Segmentation of the Rheumatoid Arthritis Stem Cell Therapy Market

The presented report dissects the Rheumatoid Arthritis Stem Cell Therapy market into different segments and ponders over the current and future prospects of each segment. The report depicts the year-on-year growth of each segment and touches upon the different factors that are likely to influence the growth of each market segment. Further, projections are made taking into account the impact of the COVID-19 pandemic on the each market segment.

The various segments of the Rheumatoid Arthritis Stem Cell Therapy market analyzed in the report include:

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Important doubts related to the Rheumatoid Arthritis Stem Cell Therapy market clarified in the report:

Why Choose Fact.MR

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Original post:
COVID-19 Outbreak Bestows Lucrative Opportunities to Rheumatoid Arthritis Stem Cell Therapy Market; Demand to Remain High Post Pandemic - Latest...

Read More...

Where did Covid-19 come from? What we know about its origins – The Guardian

May 1st, 2020 9:46 pm

Why are the origins of the pandemic so controversial?

How Covid-19 began has become increasingly contentious, with the US and other allies suggesting China has not been transparent about the origins of the outbreak.

Donald Trump, the US president, has given credence to the idea that intelligence exists suggesting the virus may have escaped from a lab in Wuhan, although the US intelligence community has pointedly declined to back this up. The scientific community says there is no current evidence for this claim.

This follows reports that the White House had been pressuring US intelligence community on the claim, recalling the Bush administrations pressure to stove pipe the intelligence before the war in Iraq.

A specific issue is that the official origin story doesnt add up in terms of the initial epidemiology of the outbreak, not least the incidence of early cases with no apparent connection to the Wuhan seafood market, where Beijing says the outbreak began. If these people were not infected at the market, or via contacts who were infected at the market, critics ask, how do you explain these cases?

Two laboratories in Wuhan studying bat coronaviruses have come under the spotlight. The Wuhan Institute of Virology (WIV) is a biosecurity level 4 facility the highest for biocontainment and the level 2 Wuhan Centre for Disease Control, which is located not far from the fish market, had collected bat coronavirus specimens.

Several theories have been promoted. The first, and wildest, is that scientists at WIV were engaged in experiments with bat coronavirus, involving so-called gene splicing, and the virus then escaped and infected humans. A second version is that sloppy biosecurity among lab staff and in procedures, perhaps in the collection or disposal of animal specimens, released a wild virus.

The scientific consensus rejecting the virus being engineered is almost unanimous. In a letter to Nature in March, a team in California led by microbiology professor Kristian Andersen said the genetic data irrefutably shows that [Covid-19] is not derived from any previously used virus backbone in other words spliced sections of another known virus.

Far more likely, they suggested, was that the virus emerged naturally and became stronger through natural selection. We propose two scenarios that can plausibly explain the origin of Sars-CoV-2: natural selection in an animal host before zoonotic [animal to human] transfer; and natural selection in humans following zoonotic transfer.

Peter Ben Embarek, an expert at the World Health Organization in animal to human transmission of diseases, and other specialists also explained to the Guardian that if there had been any manipulation of the virus you would expect to see evidence in both the gene sequences and also distortion in the data of the family tree of mutations a so-called reticulation effect.

In a statement to the Guardian, James Le Duc, the head of the Galveston National Laboratory in the US, the biggest active biocontainment facility on a US academic campus, also poured cold water on the suggestion.

There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly originated from nature, given its high similarity to other known bat-associated coronaviruses, he said.

The accidental release of a wild sample has been the focus of most attention, although the evidence offered is at best highly circumstantial.

The Washington Post has reported concerns in 2018 over security and management weakness from US embassy officials who visited the WIV several times, although the paper also conceded there was no conclusive proof the lab was the source of the outbreak.

Le Duc, however, paints a different picture of the WIV. I have visited and toured the new BSL4 laboratory in Wuhan, prior to it starting operations in 2017- It is of comparable quality and safety measures as any currently in operation in the US or Europe.

He also described encounters with Shi Zhengli, the Chinese virologist at the WIV who has led research into bat coronaviruses, and discovered the link between bats and the Sars virus that caused disease worldwide in 2003, describing her as fully engaged, very open and transparent about her work, and eager to collaborate.

Maureen Miller, an epidemiologist who worked with Shi as part of a US-funded viral research programme, echoed Le Ducs assessment. She said she believed the lab escape theory was an absolute conspiracy theory and referred to Shi as brilliant.

While the experts who spoke to the Guardian made clear that understanding of the origins of the virus remained provisional, they added that the current state of knowledge of the initial spread also created problems for the lab escape theory.

When Peter Forster, a geneticist at Cambridge, compared sequences of the virus genome collected early in the Chines outbreak and later globally he identified three dominant strains.

Early in the outbreak, two strains appear to have been in circulation at roughly at the same time strain A and strain B with a C variant later developing from strain B.

But in a surprise finding, the version with the closest genetic similarity to bat coronavirus was not the one most prevalent early on in the central Chinese city of Wuhan but instead associated with a scattering of early cases in the southern Guangdong province.

Between 24 December 2019 and 17 January 2020, Forster explains, just three out of 23 cases in Wuhan were type A, while the rest were type B. In patients in Guangdong province, however, five out of nine were found to have type A of the virus.

The very small numbers notwithstanding, said Forster, the early genome frequencies until 17 January do not favour Wuhan as an origin over other parts of China, for example five of nine Guangdong/Shenzhen patients who had A types.

In other words, it still remains far from certain that Wuhan was even necessarily where the virus first emerged.

The pandemic has exacerbated existing geopolitical struggles, prompting a disinformation war that has drawn in the US, China, Russia and others.

Journalists and scientists have been targeted by people with an apparent interest in pushing circumstantial evidence related to the viruss origins, perhaps as part of this campaign and to distract from the fact that few governments have had a fault-free response.

The current state of knowledge about coronavirus and its origin suggest the most likely explanation remains the most prosaic. Like other coronaviruses before, it simply spread to humans via a natural event, the starting point for many in the scientific community including the World Health Organization.

Further testing in China in the months ahead may eventually establish the source of the outbreak. But for now it is too early.

Read the original post:
Where did Covid-19 come from? What we know about its origins - The Guardian

Read More...

The Pandemic and America’s Response to Future Bioweapons – War on the Rocks

May 1st, 2020 9:46 pm

In the fall of 2011, Dr. Ron Fouchier developed one of the most dangerous viruses you can make. Fouchier, a Dutch virologist at the Erasmus Medical Center in Rotterdam, claimed that his team had done something really, really stupid and mutated the hell out of H5N1.At nearly the same time, Dr. Yoshihiro Kawaoka at the University of Wisconsin-Madison worked on grafting the H5N1 spike gene onto 2009 H1N1 swine flu, creating another transmissible, virulent strain.

Despite only 600 human cases of the H5N1 (bird flu) virus in the previous two decades, the exceptionally high mortality rate greater than 50 percent pushed the National Science Advisory Board for Biosecurity to block the publication of both teams research. After a heated debate in the scientific community, the World Health Organization deemed it safe to publish the findings. While Kawaokas paper appeared in the journal Nature, Fouchiers original study appeared in Science. Although both teams generated viruses that were not as lethal as their wild forms, critics worried that the papers would enable rogue scientists to replicate the manipulations and weaponize a more contagious virus.

While some arms control experts like Graham Allison believe that terrorists are more likely to be able to obtain and use a biological weapon than a nuclear weapon, others have dismissed bioweapons due to dissemination issues, exemplified in failed biological attacks with botulinum toxin and anthrax by the terrorist group Aum Shinrikyo. Furthermore, studies from the U.S. Office of Technology Assessment indicated that bioweapons could cause tens of thousands of deaths under ideal environmental conditions but would not severely undermine critical infrastructure. In 2012, Dr. Anthony Fauci, the longtime director of the National Institute of Allergy and Infectious Diseases, argued that the benefits in vaccine advancement from Fouchiers research outweighed the risks of nefarious use.

Today, however, Fauci is at the helm of Americas response to a global pandemic. Although the world has never experienced a mass-casualty bioweapons incident, COVID-19 has caused sustained, strategic-level harm. In the absence of a vaccine, it has killed more than 60,000 Americans and forced over 30 million Americans into unemployment. The isolation of large segments of society has crippled the economy and traditional sources of American power: domestically, cascading, second- and third-order effects plague critical national infrastructure; and internationally, power projection wanes, epitomized by the U.S. Navys sidelining of the USS Theodore Roosevelt.

While the SARS-CoV-2 virus that causes COVID-19 is not a bioweapon, technological advances increase the possibility of a future bioweapon wreaking similar strategic havoc. Specifically, advancements in genetic engineering and delivery mechanisms may lead to the more lethal microorganisms and toxins and, consequently, the most dangerous pandemic yet. Therefore, the United States should develop a new strategy to deter and disrupt biological threats to the nation.

Engineering the Next Pandemic

Although a bioweapon-induced pandemic seems unlikely in the short term, preparedness for future attacks begins with understanding the possible threat. According to the Centers for Disease Control, bioweapons are intentionally released microorganisms bacteria, viruses, fungi or toxins, coupled with a delivery system, that cause disease or death in people, animals, or plants. In contrast to other chemical, biological, radiological, or nuclear weapons, they have distinctive dangerous characteristics: miniscule quantities even 10-8 milligrams per person can be lethal; the symptoms can have a delayed onset; and ensuing waves of infection can manifest beyond the original attack site. The Centers for Disease Control grouped over 30 weaponizable microorganisms and toxins into three threat categories based on lethality, transmissibility, and necessity for special public heath interventions. While Categories A and B cover existing high and moderate threats, respectively, Category C focuses on emerging pathogens, like the Nipah virus and hantavirus, that could be engineered for mass dissemination. Historically, though, bioweapons were relatively unsophisticated and inexpensive when compared to chemical and nuclear production chains, which explains their protracted use.

One of the earliest examples of biological warfare occurred over 2,000 years ago, when Assyrians infected enemy wells with rye ergot fungus. In 1763, the British army presented smallpox-infested blankets to Native American during the Siege of Fort Pitt. During World War II, the Japanese army poisoned over 1,000 water wells in Chinese villages to study typhus and cholera outbreaks. In 1984, the Rajneeshee cult contaminated salad bars in Oregon restaurants with Salmonella typhimurium, causing 751 cases of enteritis. Most recently, Bacillus anthracis spores sent in the U.S. postal system induced 22 cases of anthrax and five deaths in 2001, and three U.S. Senate office buildings shut down in February 2004 after the discovery of ricin in a mailroom.

Despite this history of usage, the challenge of disseminating the biological agent has, thus far, meant that bioweapons attacks have not produced high casualties. Bioweapons can be delivered in numerous ways: direct absorption or injection into the skin, inhalation of aerosol sprays, or via consumption of food and water. The most vulnerable and often most lethal point of entry is the lungs, but particles must fall within a restrictive size range of 1 micrometer to 5 micrometers to penetrate them. Fortunately, most biological agents break down quickly in the environment through exposure to heat, oxidation, and pollution, coupled with the roughly 50 percent loss of the microorganism during aerosol dissemination or 90 percent loss during explosive dissemination.

The revolution in genetic engineering provides a path for overcoming delivery issues and escalating a biological attack into a pandemic. First, tools for analyzing and altering a microorganisms DNA or RNA are available and affordable worldwide. The introduction of clustered regularly interspersed short palindromic repeats (CRISPR) a technique that acts like scissors or a pencil to alter DNA sequences and gene functions in 2013 made biodefense more challenging. Even as experienced researchers struggle to control clustered regularly interspersed short palindromic repeats and prevent unintended effects, malevolent actors with newfound access can attempt to manipulate existing agents to increase contagiousness; improve resistance to antibiotics, vaccines, and anti-virals; enhance survivability in the environment; and develop means of mass production. Infamously, Australian researchers in 2001 endeavored to induce infertility in mice by inserting the interleukin-4 gene into the mousepox virus. Instead, they inadvertently altered the virus to become more virulent and kill previously vaccinated mice, insinuating that the same could be done with smallpox for humans.

Moving one step further, genetic engineering raises the possibility of creating completely new biological weapons from scratch via methods similar to the test-tube synthesis of poliovirus in 2002. It is, thankfully, hard to use this process to create agents that can kill humans. However, genetic engineering can be used to create non-lethal weapons that, when coupled with longer-range delivery devices, could kill crops and animals, and destroy materials fuel, plastic, rubber, stealth paints, and constructional supplies that are critical to the economy.

Skeptics might question why a rational adversary would risk creating and employing bioweapons that are unpredictable and relatively hard to deliver to a target. First, some potential terrorists are irrational in the sense that death does not deter their service to a higher purpose; or, they may simply show a willingness to carry out orders from a state sponsor or a lack of concern for public opinion. Second, future state aggressors might genetically engineer a vaccine to immunize their populations prior to unleashing a bioweapon so that the attack would only be indiscriminate within targeted nations. Third, the unprecedented harm done by COVID-19 demands a transformation of 9/11-era priorities to recognize that preparing for domestic threats like pandemics will be far greater concerns for most Americans than threats from foreign adversaries. Bioweapons combine the worst of these national and international threats.

Ultimately, for a bioweapon attack to turn into a pandemic like the SARS-CoV-2 virus, three initial conditions must be met: first, the microorganism or toxin must not have an effective remedy available; second, it must be easily transmittable; and third, it must be fatal for some victims. Whereas a number of natural-born microbes satisfied these conditions in the past, it is possible for a genetically engineered bioweapon to have the same strategic impact in the future.

Prepare for the Worst

John Barrys The Great Influenza: The Story of the Deadliest Pandemic in History provides insight into what the world might look like in the approaching age of biological attacks. It portrays how researchers failed to counter the 1918 flu strain while it spread to one-third of the global population. With a mortality rate of approximately 20 percent, the Spanish flus viral mutations proved especially fatal for military members with strong immune systems. Young people with previous exposure to milder flu strains likely suffered from immunological memory, which prompted a dysregulated immune response to the 1918 strain. At the time of the books publication in 2004, President George W. Bush took notice.

In a November 2005 speech at the National Institutes of Health, with Fauci notably in attendance, Bush warned, If we wait for a pandemic to appear, it will be too late to prepare. And one day many lives could be needlessly lost because we failed to act today. Similarly, the government should prepare now to respond to a future bioweapon attack whether from terrorism or interstate warfare. This preparation ought to proceed along three categories of action: deterrence, disruption, and defense.

Deterrence

In the realm of biological warfare, the most effective way to save lives is to persuade an adversary that an attack will not succeed. Specifically, deterrence by denial makes the act of aggression unprofitable by rendering the target harder to take, harder to keep, or both. To this end, the United States can harden its biowarfare response by increasing interagency cooperation, wargaming the resulting plans, and compiling the materials required for their execution.

The Department of Defense the largest agency in the U.S. government is the logical choice to organize a whole-of-government approach to countering bioweapons. Last November, the Pentagon released the Joint Countering Weapons of Mass Destruction doctrine, which outlined how the military will synchronize its response with governmental stakeholders like the Director of National Intelligence, the United States Agency for International Development, the Department of Energy, and the Department of Health and Human Services. Partnerships, however, should expand beyond governmental agencies via a military joint task force with leadership from the medical community and information technology professionals. The Department of Homeland Security and Centers for Disease Control should coordinate with medical schools to incorporate more curriculum and periodic exercises on pandemic control and emergency response. Likewise, the Pentagon should develop best practices for establishing communications, sustaining services, and combatting disinformation during a pandemic.

While increased interagency cooperation will encourage more robust pandemic plans, wargaming is key to testing how such plans fare in a biowarfare crisis. Last September, the Naval War College in Newport, Rhode Island, ran a two-day wargame called Urban Outbreak 2019, in which 50 experts combatted a notional pandemic. Even though this scenario had a vaccine available from the start, the findings offer prescient insight into actions surrounding COVID-19 particularly that experienced leaders may display significant resistance when encountering first-time situations or prevent troops from interfacing with infected populations. Military and agency leaders should use wargames with worst-case, extraordinary bioweapons to recognize and overcome inherent biases while simultaneously brainstorming how to lower infection rates, implement quarantines, and communicate best practices to the public.

Wargaming should also help planners identify which materials require stockpiling ahead of the next pandemic. COVID-19, for example, exposed shortages of durable protective masks, hand sanitizer, antiseptic wipes, and surface cleaners. The 300,000 businesses that make up the defense industrial base should prepare for the research, production, and delivery of personal protective equipment whenever shortages arise. They should also expect to be tapped for antibiotic, vaccine, or anti-viral production, depending on the nature of the bioweapon.

Disruption

A pandemic is a lot like a forest fire, Bush said in his 2005 speech. If caught early it might be extinguished with limited damage. If deterrence fails, American policy should focus on the early detection and disruption of bioweapons. To achieve this goal, the United States can advocate for increased verification measures and high-performing information operations.

Although the Biological Weapons Convention went into force in 1975 and has 182 state parties, the treaty lacks verification procedures and merely prohibits the production, stockpiling, and transfer of biological agents for warfare purposes. Since the treaty permits defensive research, a major challenge is the dual-use nature of production chains, wherein the technology for allowable projects also supports harmful weapons. Given the complex and sensitive nature of vital biological research, the United States has chosen not to support the establishment of a verification agency for routine facility inspections. This choice stands in contrast to the American approach toward the Organization for the Prohibition of Chemical Weapons and the International Atomic Energy Agency, both of which have robust verification mechanisms. Without this accountability, however, the Soviet Union established the Biopreparat after signing the Biological Weapons Convention treaty, employing over 50,000 people to produce tons of anthrax bacilli, smallpox virus, and multidrug-resistant plague bacteria.

To assist with the early warning of bioweapon threats, the United States should improve its understanding of international biological facilities. For instance, International Gene Synthesis Consortium members use automated software and a common protocol to screen their customers, as well as synthetic gene orders with dangerous sequences from the Regulated Pathogen Database. Particular attention should be paid to biosafety level-4 and biosafety level-3 labs around the world, where human error has led to the unintentional escape of pathogens. The U.K. foot and mouth outbreak of 2007 was traced to a faulty waste disposal system at Pirbright Laboratory in Surrey. Additionally, SARS laboratory accidents occurred in China in 2004. Increasing the priority given to intelligence gathering and analysis related to bioweapons would be an important step in the right direction.

Defense

If the United States is unable to deter or disrupt a bioweapons attack, it should be prepared to execute a strong defense against it. First and foremost, the military ought to maintain the health of its servicemembers through a COVID-19-inspired operational plan for screening and quarantine. This plan would facilitate prompt and sustained emergency responses and combat operations, including key missions like strategic nuclear deterrent patrols. Domestically, the military will need to assist in civil support, law enforcement, border patrol, and the defense of critical infrastructure. Internationally, the Defense Department will serve as a logistics powerhouse.

At home, the armed forces have the manpower and experience to aid in a variety of national security sectors. In addition to the deployment of U.S. Navy hospital ships to New York City and Los Angeles during COVID-19, the National Guard has conducted drive-through testing, delivered water to vulnerable populations, and carried out state governors law enforcement orders for curfews and quarantines. For critical national infrastructure, the military will serve as first responders to newfound issues with electrical generation, water purification, sanitation, and information technology.

Abroad, the military could benefit from military-to-military planning and exercises with what former Supreme Allied Commander Europe Adm. (ret.) James Stavridis calls the equivalent of a North Atlantic Treaty Organization against pandemics. In the absence of this organization, the Air Force can coordinate logistics efforts to move overseas medical supplies to the United States and bring Americans home.

The United States should draw lessons learned from past international pandemic responses. The cholera outbreak among half a million Haitians following a 2010 earthquake demonstrated that the American military could work with international military counterparts to regenerate critical infrastructure in other countries. The Ebola outbreak in West Africa in 2014 extended that cooperation to nongovernmental organizations like the Red Cross, Doctors Without Borders, and Project Hope.

Successful military cooperation abroad will fulfill basic international needs and build trust for peaceful scientific cooperation, shifting the focus to future questions like whether the bioweapon is mutating, how environmental factors affect its spread, if infected people develop short- or long-term immunity, and which mitigation efforts are effective. Successful in-situ defense will fill interdisciplinary gaps in deterrence and disruption while a layered 3D approach will determine how well the world fares during the most dangerous pandemic yet.

Conclusion

The COVID-19 pandemic foreshadows how a future bioweapons attack would unfold without proper preparation. Planning for a bioweapons attack is incredibly difficult bioweapons can be delivered by states or terrorist groups, originate from existing agents or from scratch, and can be delivered in a number of different ways. While establishing a permanent military joint task force with appropriate funding is an achievable first step, combined efforts in deterrence, disruption, and defense are key in anticipating these variables of an attack and surviving it once unleashed.

Lt. Andrea Howard is a nuclear submarine officer aboard the USS Ohio. Following her graduation from the U.S. Naval Academy in 2015, she was a Marshall Scholar at the University of Oxford and Kings College London, where she focused on the intersection of technology, security, and diplomacy in weapons of mass destruction policy. Lt. Howard won the U.S. Naval Institutes 2019 Emerging and Disruptive Technologies Essay Contest and is a member of the Seattle Chapter of the Truman National Security Project.

Image: North Carolina Air National Guard (Photo by Tech. Sgt. Julianne Showalter)

Read the original:
The Pandemic and America's Response to Future Bioweapons - War on the Rocks

Read More...

The pieces of the puzzle of covid-19s origin are coming to light – The Economist

May 1st, 2020 9:46 pm

Apr 29th 2020

Editors note: The Economist is making some of its most important coverage of the covid-19 pandemic freely available to readers of The Economist Today, our daily newsletter. To receive it, register here. For our coronavirus tracker and more coverage, see our hub

AURIC GOLDFINGER, villain of the novel which bears his name, quotes a vivid Chicago aphorism to James Bond: Once is happenstance, twice is coincidence, the third time its enemy action.

Until 2002 medical science knew of a handful of coronaviruses that infected human beings, none of which caused serious illness. Then, in 2002, a virus now called SARS-CoV surfaced in the Chinese province of Guangdong. The subsequent outbreak of severe acute respiratory syndrome (SARS) killed 774 people around the world before it was brought under control. In 2012 another new illness, Middle Eastern respiratory syndrome (MERS), heralded the arrival of MERS-CoV, which while not spreading as far and as wide as SARS (bar an excursion to South Korea) has not yet been eliminated. It has killed 858 people to date, the most recent of them on February 4th.

The third time, it was SARS-CoV-2, now responsible for 225,000 covid-19 deaths. Both SARS-CoV and MERS-CoV are closely related to coronaviruses found in wild bats. In the case of SARS-CoV, the accepted story is that the virus spread from bats in a cave in Yunnan province into civets, which were sold at markets in Guangdong. In the case of MERS-CoV, the virus spread from bats into camels. It now passes regularly from camels to humans, which makes it hard to eliminate, but only spreads between people in conditions of close proximity, which makes it manageable.

Third time unluckyAn origin among bats seems overwhelmingly likely for SARS-CoV-2, too. The route it took from bat to human, though, has yet to be identified. If, like MERS-CoV, the virus is still circulating in an animal reservoir, it could break out again in the future. If not, some other virus will surely try something similar. Peter Ben Embarek, an expert on zoonoses (diseases passed from animals to people) at the World Health Organisation, says that such spillovers are becoming more common as humans and their farmed animals push into new areas where they have closer contact with wildlife. Understanding the detail of how such spillovers occur should provide insights into stopping them.

In some minds, though, the possibility looms of enemy action on the part of something larger than a virus. Since the advent of genetic engineering in the 1970s, conspiracy theorists have pointed to pretty much every new infectious disease, from AIDS to Ebola to MERS to Lyme disease to SARS to Zika, as being a result of human tinkering or malevolence.

The politics of the covid-19 pandemic mean that this time such theories have an even greater appeal than normal. The pandemic started in China, where the governments ingrained urge to cover problems up led it to delay measures that might have curtailed its spread. It has claimed its greatest toll in America, where the recorded number of covid-19 deaths already outstrips the number of names on the Vietnam War Memorial in Washington, DC.

These facts would have led to accusations ringing out across the Pacific come what may. What makes things worse is a suspicion in some quarters that SARS-CoV-2 might in some way be connected to Chinese virological research, and that saying so may reapportion any blame.

There is no evidence for the claim. Western experts say categorically that the sequence of the new viruss genomewhich Chinese scientists published early on, openly and accuratelyreveals none of the telltales genetic engineering would leave in its wake. But it remains a fact that in Wuhan, where the outbreak was first spotted, there is a laboratory where scientists have in the past deliberately made coronaviruses more pathogenic.

Such research is carried out in laboratories around the world. Its proponents see it as a vital way of studying the question that covid-19 has brought so cruelly into the spotlight: how does a virus become the sort of thing that starts a pandemic? That some of this research has been done at the Wuhan Institute of Virology (WIV) seems all but certainly a coincidence. Without a compelling alternative account of the diseases origin, however, there is room for doubt to remain.

The 4% differenceThe origin of the virus behind the 2003 SARS outbreakclassic SARS, as some virologists now wryly call itwas established in large part by Shi Zhengli, a researcher at WIV sometimes referred to in Chinese media as the bat lady. Over a period of years she and her team visited remote locations all across the country in search of a close relative of SARS-CoV in bats or their guano. They found one in a cave full of horseshoe bats in Yunnan.

It is in the collection of viral genomes assembled during those studies that scientists have now found the bat virus closest to SARS-CoV-2. A strain called RaTG13 gathered in the same cave in Yunnan shares 96% of its genetic sequence with the new virus. RaTG13 is not that viruss ancestor. It is something more like its cousin. Edward Holmes, a virologist at the University of Sydney, estimates that the 4% difference between the two represents at least 20 years of evolutionary divergence from some common antecedent, and probably something more like 50.

Although bats could, in theory, have passed a virus descended from that antecedent directly to humans, experts find the idea unlikely. The bat viruses look different from SARS-CoV-2 in a specific way. In SARS-CoV-2 the spike protein on the viral particles surface has a receptor-binding domain (RBD) that is adept at sticking to a particular molecule on the surface of the human cells the virus infects. The RBD in bat coronaviruses is not the same.

One recent study suggests that SARS-CoV-2 is the product of natural genomic recombination. Different coronaviruses infecting the same host are more than happy to swap bits of genome. If a bat virus similar to RaTG13 got into an animal already infected with a coronavirus which boasted an RBD better suited to infecting humans, a basically batty virus with a more human-attuned RBD might well arise. That is what SARS-CoV-2 looks like.

Early on, it was widely imagined that the intermediate host was likely to be a species sold in Wuhans Huanan Seafood and Wildlife Market, a place where all sorts of creatures, from raccoon dogs to ferret badgers, and from near and far, are crammed together in unsanitary conditions. Many early human cases of covid-19 were associated with this market. Jonathan Epstein, vice-president of science with EcoHealth Alliance, an NGO, says of 585 swabs of different surfaces around the market, about 33 were positive for SARS-CoV-2. They all came from the area known to sell wild animals. That is pretty much as strong as circumstantial evidence gets.

The first animal to come under serious suspicion was the pangolin. A coronavirus found in pangolins has an RBD essentially identical to that of SARS-CoV-2, suggesting that it might have been the virus with which the bat virus recombined on its way to becoming SARS-CoV-2. Pangolins are used in traditional medicine, and though they are endangered, they can nonetheless be found on menus. There are apparently no records of them being traded at the Huanan market. But given that such trading is illegal, and that such records would now look rather incriminating, this is hardly proof that they were not.

The fact that pangolins are known to harbour viruses from which SARS-CoV-2 could have picked up its human-compatible RBD is certainly suggestive. But a range of other animals might harbour such viruses, too; its just that scientists have not yet looked all that thoroughly. The RBD in SARS-CoV-2 is useful not only for attacking the cells of human beings and, presumably, pangolins. It provides access to similar cells in other species, too. In recent weeks SARS-CoV-2 has been shown to have found its way from humans into domestic cats, farmed mink and a tiger. There is some evidence that it can actually pass between cats, which makes it conceivable that they were the intermediatethough there is as yet no evidence of a cat infecting a human.

The markets appeal as a site for the human infections behind the Wuhan outbreak remains strong; a market in Guangdong is blamed for the spread of SARS. Without a known intermediate, though, the evidence against it remains circumstantial. Though many early human cases were associated with the market, plenty were not. They may have been linked to people with ties to the market in ways not yet known. But one cannot be sure.

Where to begin?The viral genomes found in early patients are so similar as to suggest strongly that the virus jumped from its intermediate host to people only once. Estimates based on the rate at which genomes diverge give the earliest time for this transfer as early October 2019. If that is right there were almost certainly infections which were not serious, or which did not reach hospitals, or which were not recognised as odd, before the first official cases were seen in Wuhan at the beginning of December. Those early cases may have taken place elsewhere.

Ian Lipkin, the boss of the Centre for Infection and Immunity at Columbia University, in New York, is working with Chinese researchers to test blood samples taken late last year from patients with pneumonia all around China, to see if there is any evidence for the virus having spread to Wuhan from somewhere else. If there is, then it may have entered Huanan market not in a cage, but on two legs. The market is popular with visitors as well as locals, and is close to Hankou railway station, a hub in Chinas high-speed rail network.

Further research may make when, where and how the virus got into people clearer. There is scope for a lot more virus hunting in a wider range of possible intermediate species. If it were possible to conduct detailed interviews with those who came down with the earliest cases of covid-19, that genetic sampling could be better aimed, says Dr Embarek, and with a bit of luck one might get to the source. But the time needed to do this, he adds, might be quick, or it might be extremely long.

If it turns out to have originated elsewhere, the new viruss identification during the early stages of the Wuhan epidemic may turn out to be thanks to the citys concentration of virological know-howknow-how that is now surely being thrown into sequencing more viruses from more sources. But until a satisfactory account of a natural spillover is achieved, that same concentration of know-how, at WIV and another local research centre, the Wuhan Centre for Disease Control and Prevention, will continue to attract suspicion.

In 2017 WIV opened the first biosecurity-level 4 (BSL-4) laboratory in Chinathe sort of high-containment facility in which work is done on the most dangerous pathogens. A large part of Dr Shis post-SARS research there has been aimed at understanding the potential which viruses still circulating among bats have to spill over into the human population. In one experiment she and Ge Xingyi, also of the WIV, in collaboration with American and Italian scientists, explored the disease-like potential of a bat coronavirus, SHC014-CoV, by recombining its genome with that of a mouse-infecting coronavirus. The WIV newsletter of November 2015 reported that the resulting virus could replicate efficiently in primary human airway cells and achieve in vitro titres equivalent to epidemic strains of SARS-CoV. In early April this newsletter and all others were removed from the institutes website.

This work, results from which were also published in Nature Medicine, demonstrated that SARS-CoVs jump from bats to humans had not been a fluke; other bat coronaviruses were capable of something similar. Useful to know. But giving pathogens and potential pathogens extra powers in order to understand what they may be capable of is a controversial undertaking. These gain of function experiments, their proponents insist, have important uses such as understanding drug resistance and the tricks viruses employ to evade the immune system. They also carry obvious risks: the techniques on which they depend could be abused; their products could leak. The creation of an enhanced strain of bird flu in 2011 in an attempt to understand the peculiar virulence of the flu strain responsible for the pandemic of 1918-19 caused widespread alarm. America stopped funding gain-of-function work for several years.

Filippa Lentzos, who studies biomedicine and security at Kings College, London, says the possibility of SARS-CoV-2 having an origin connected with legitimate research is being discussed widely in the world of biosecurity. The possibilities speculated about include a leak of material from a laboratory and also the accidental infection of a human being in the course of work either in a lab or in the field.

Leaks from laboratories, including BSL-4 labs, are not unheard of. The worlds last known case of smallpox was caused by a leak from a British laboratory in 1978. An outbreak of foot and mouth disease in 2007 had a similar origin. In America there have been accidental releases and mishandlings involving Ebola, and, from a lower-containment-level laboratory, a deadly strain of bird flu. In China laboratory workers seem to have been infected with SARS and transmitted it to contacts outside on at least two occasions.

Heres one I made earlierThings doubtless leak out of labs working at lower biosafety levels, too. But how much they do so is unknown, in part because people worry about them less. And as in other parts of this story the unknown is a Petri dish in which speculation can grow. This may be part of the reason for interest in a lab at the Wuhan Centre for Disease Control and Prevention. A preprint published on ResearchGate, a website, by two Chinese scientists and subsequently removed suggested that work done there may have been cause for concern. This lab is reported to have housed animalsincluding, for one study, hundreds of bats from Hubei and Zhejiang provincesand to have specialised in pathogen collection.

Richard Pilch, who works on chemical and biological weapons non-proliferation at the Middlebury Institute of International Studies, in California, says that there is one feature of the new virus which might conceivably have arisen during passaging experiments in which pathogens are passed between hosts so as to study the evolution of their ability to spread. This is the polybasic cleavage site, which might enhance infectivity. SARS-CoV-2 has such a site on its spike protein. Its closest relatives among bat coronaviruses do not. But though such a cleavage site could have arisen through passaging there is no evidence that, in this case, it did. It could also have evolved in the normal way as the virus passed from host to host. Dr Holmes, meanwhile, has said that there is no evidence that SARS-CoV-2...originated in a laboratory in Wuhan, China. Though others have speculated about coincidences and possibilities, no one has been able, as yet, to undermine that statement.

Many scientists think that with so many biologists actively hunting for bat viruses, and gain-of-function work becoming more common, the world is at increasing risk of a laboratory-derived pandemic at some point. One of my biggest hopes out of this pandemic is that we address this issueit really worries me, says Dr Pilch. Today there are around 70 BSL-4 sites in 30 countries. More such facilities are planned.

Again, though, it is necessary to consider the unknown. Every year there are tens of thousands of fatal cases of respiratory disease around the world of which the cause is mysterious. Some of them may be the result of unrecognised zoonoses. The question of whether they really are, and how those threats may stack up, needs attention. That attention needs laboratories. It also needs a degree of open co-operation that America is now degrading with accusations and reductions in funding, and that China has taken steps to suppress at source. That suppression has done nothing to help the country; indeed, by supporting speculation, it may yet harm it.

Dig deeper:

For our latest coverage of the covid-19 pandemic, register for The Economist Today, our daily newsletter, or visit our coronavirus tracker and story hub

Read more:
The pieces of the puzzle of covid-19s origin are coming to light - The Economist

Read More...

Heres What’s Coming from Marvel on Disney+ in May – Marvel Entertainment

May 1st, 2020 9:46 pm

Looking for more Marvel things to add to your ever-growing Disney+ queue? For the month of May, two Marvel series are hitting the streaming service and theyre perfect to watch solo, with your family, or with friends hundreds of miles away watch-along, anyone?

Fury Files drops on Disney+ on Friday, May 15, and you shouldnt be surprised that Nick Fury has files on every single Marvel Super Hero. Fury Files gives viewers top-secret access to S.H.I.E.L.D. intel on key Marvel heroes and villains. All of this is told by none other than the mysterious Fury, bringing together a mix of animation and motion comic art! Looking to download a bunch of information about every single hero? Furys got you covered.

If youve already watched the first season of Marvel's Future Adventures on Disney+, get ready for the second. All 13 episodes of Season 2 land on Disney+ on May 22, 2020. Marvels Future Avengers follows Makoto, a young boy who developed superpowers from a Hydra genetic engineering experiment, and his friends Adi and Chloe as they train under Earth's Mightiest Heroes as apprentices, dubbing themselves the "Future Avengers."

[!youtube=VLrFf-T2ef4]

These two series join an ever-growing roster of Marvel movies, series, and shorts you can watch on Disney+. Whether youre looking to watch something from the Marvel Cinematic Universe or relive animated shows from your childhood, theres something for everyone!

Disney+ offers subscribers high-quality and commercial-free viewing, up to four concurrent streams, unlimited downloads on up to ten devices, personalized recommendations, and the ability to set up to seven different profiles. Additionally, parents have the ability to set Kids Profiles that create an easy-to-navigate interface to access age-appropriate content.

Sign up for Disney+ and start streaming now! And be sure to follow Disney+ on Facebook, Twitter, and Instagram for more.

Read the original post:
Heres What's Coming from Marvel on Disney+ in May - Marvel Entertainment

Read More...

Covid-19 treatment on the horizon but vaccine remains elusive – Pharmaceutical Technology

May 1st, 2020 9:46 pm

The Covid-19 pandemic that has swept the globe has led to a massive search for a drug with which to combat this deadly virus, yet despite many pharmaceutical companies continuing to pour their resources into a cure for this virus, the development of prophylactic vaccines for Covid-19 appears to be lagging.

According to GlobalDatas Pharma Intelligence Center Pipeline Database and the Coronavirus Disease 2019 (Covid-19) dashboard, there are, as of 23 April, 80 therapeutic drugs in Phases I, II, and III that may be able to treat Covid-19, but only nine prophylactic vaccine drugs in Phases I and II, indicating that while a possible cure for Covid-19 may be imminent, a prophylactic vaccine to combat the pandemic may need more time to come to fruition.

The response from pharma and biotech companies globally to finding a Covid-19 vaccine has contributed to 438 unique drugs to treat Covid-19: 298 therapeutic drugs and 140 prophylactic vaccines, spread across all stages of development (Discovery, Preclinical, Phase I, Phase II, and Phase III), which is especially remarkable considering that the virus was only identified at the beginning of this year. In these unprecedented times, this massive pipeline in such a short time is demonstrative of the pharmaceutical industry compiling resources and talent, to finding a drug to combat this pandemic of the Covid-19 virus.

Therapeutic drugs account for two thirds of the entire pipeline, with prophylactic vaccines accounting for the remaining third of the current Covid-19 pipeline. Therapeutic drugs have 73% of their pipeline in early-stage development (Preclinical and Discovery) and 27% in late-stage development (Phases I, II, and III); despite the majority of drugs being in early stages, there is a viable pipeline of late-stage drugs that may in the coming months offer a solution to the ongoing crisis. The key drugs to watch are two small moleculebased drugs, remdesivir by Gilead Sciences Inc. and favipiravir by Fujifilm Toyama Chemical Co Ltd, and sarilumab, a monoclonal antibody by Regeneron Pharmaceutical, all three of which are currently in Phase III. At the same time as they are being developed for the Covid-19 virus, these drugs are also being developed for multiple other indications.

In direct contrast, the prophylactic vaccine pipeline largely comprises drugs in early-stage development, with 94% of the pipeline. There are currently only three drugs in Phase II, the current highest stage of development for prophylactic vaccine pipeline. These three Covid-19 vaccines are being developed by Sinovac Biotech Ltd, the University of Oxford, and the third vaccine, named CIGB-2020, is being developed by the Center for Genetic Engineering and Biotechnology. This huge disparity in late-stage and early-stage development is indicative of a lack of focus within the industry for vaccines in comparison to the therapeutic drugs pipeline. The massive global response towards the coronavirus and the massive increase in the therapeutic pipeline, however, does mean that this state of affairs is liable to change in the coming weeks. As this pandemic continues and governments and pharmaceutical companies continue to look for ways to combat Covid-19, the therapeutic landscape is sure to change, but as of now any hopes for a fast vaccine may not materialize.

You can view more information on the Covid-19 therapeutic landscape on GlobalDatas Pharma Intelligence Center Pipeline Database and the Coronavirus Disease 2019 (Covid-19) dashboard where the most up-to-date and latest information on drugs, trials, and news on Covid-19 can be found.

GlobalData is this websites parent business intelligence company.

More here:
Covid-19 treatment on the horizon but vaccine remains elusive - Pharmaceutical Technology

Read More...

22nd Century Group to Announce First Quarter 2020 Financial Results on May 7, 2020 – GlobeNewswire

May 1st, 2020 9:46 pm

Williamsville, NY, April 28, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (22nd Century or the Company), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, will release first quarter 2020 financial results on Thursday, May 7, 2020, before the market opens. The press release will be available on 22nd Century Groups website at http://www.xxiicentury.com. In conjunction with the earnings release, the Company will host a conference call on Thursday, May 7, 2020, at 8:00 a.m. ET.

The live audio webcast will be accessible in the Events section on the Company's Investor Relations website at http://www.xxiicentury.com/investors. Participants may also listen to the live call by dialing (877) 407-6914. A replay of the call will be available until May 21, 2020 by dialing (877) 660-6853; the passcode is 13702417. An archived replay of the webcast will also be available shortly after the live event has concluded.

Investors, analysts and members of the media interested in submitting questions in advance can do so by sending an e-mail to investorrelations@xxiicentury.com.

About 22nd Century Group, Inc.22nd Century Group, Inc. (NYSE AMERICAN: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing and modern plant breeding. The Companys primary mission in tobacco is to reduce the harm caused by smoking by bringing its proprietary reduced nicotine content cigarettes with 95% less nicotine than conventional cigarettes to adult smokers in the U.S. and international markets. The Companys primary mission in hemp/cannabis is to develop proprietary hemp/cannabis plants with unique cannabinoid profiles and desirable agronomic traits and to commercialize those plants through a synergistic portfolio of strategic partnerships in the hemp/cannabis industry.

Learn more atxxiicentury.com, on Twitter@_xxiicenturyand onLinkedIn.

###

See original here:
22nd Century Group to Announce First Quarter 2020 Financial Results on May 7, 2020 - GlobeNewswire

Read More...

Cell Culture Market : Investigation and Growth Forecast until the End of 2025 Cole Reports – Cole of Duty

May 1st, 2020 9:46 pm

In this report, the Global Cell Culture Market is valued at USD 11,210.7 million in 2015 and growing at a CAGR of over 10% between 2017 and 2025.Cell Culture Market , published by Xpodence Research, provides extensive insight and analysis of the Cell Culture Market over the next eight years (2015-2025) and acts as a vital point of reference for operators or suppliers.Increasing R&D activities of healthcare, biological, and stem cell applications has enhanced the demand of molecular biological activities which is further projected to persist a vibrant aspect for market growth. Cell culture technology includes several complications including raw material supply and fully traceable botanical extracts. Also, growing attention on certifying regulatory compliances associated with environmental sustainability can impede the efficacy of the technology.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10222582

Additionally, affluence from various applications such as genetic engineering, research model systems, and continuous research related to cellular functions and stem cell research is also expected to drive the cell culture process globally. Few other factors spurring the growth includes rise in life sciences research, cell based technology advancement, cumulative cell based production, and mounting demand of cell based therapies.Rising growth in the number of regulatory approvals for cell culture-based vaccines and increasing funding for cell-based research will also influenced the market positively. Furthermore, growing application of single-use technologies and rising demand for mAbs are few factor projected to spur the market growth. Though, extensive cost involvement in cell culture research, lack of awareness for diagnosis technologies, and high contamination risks may hinder the market growth. Furthermore, optimization & handling of cell-based protocol in vitro studies will defies the market growth.

The report includes Segmentation: On the basis of product, this report displays the revenue, market share and growth rate of each type, primarily split into Consumables Instrument

On the basis on the applications, this report focuses on the status and outlook for major applications, market share and growth rate for each application, including Biopharmaceuticals Drug Development Cancer Research Culture Systems Gene Therapy Toxicity Testing Tissue Culture & Engineering Vaccine Production

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10222582

Geographic Segmentation: This report split global market into North America, Europe, Asia Pacific, the Middle East and Africa and Latin America, with revenue (Million USD), market share and growth rate of Cell Culture for these regions, from 2015 to 2025 (forecast)North America: U.S., Rest of North AmericaEurope: Germany, France, UK, rest of EuropeAsia Pacific: China, Japan, India and Rest of Asia PacificMiddle East & Africa: GCC, North Africa, South Africa and Rest of MEALatin America: Brazil and Rest of Latin America

Key players: Overview of market leaders in Cell Culture market by top manufacturers/players, with Cell Culture revenue (Million USD) and market share for each manufacturer/player; the top players including Sartorius AG, Thermo Fisher Scientific, Merck KGaA, Corning Incorporation, Sigma Aldrich Co. LLC, Promocell GmbH, GE Healthcare, Eppendorf AG, Becton, Dickinson & Company and VWR International, LLC.On the basis of end-users, the market shows the revenue, global share and growth rate of each type, majorly divided into

Request For Full Report:https://www.kennethresearch.com/sample-request-10222582

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth ResearchEmail: [emailprotected]Phone: +1 313 462 0609

Read the original:
Cell Culture Market : Investigation and Growth Forecast until the End of 2025 Cole Reports - Cole of Duty

Read More...

Rishi Kapoor succumbs to Leukemia: Here is all we know about the condition and treatment – Times of India

May 1st, 2020 9:45 pm

In an unfortunate development, actor Rishi Kapoor lost his long battle with Leukemia. As we all know, the actor had travelled to the US for his treatment earlier and came back looking younger and healed. But he has had his share of health issues ever since. The family had been referring to the treatment as marrow and today the family confirmed that the actor was struggling with leukemia. Let us first understand what leukemia is - Leukemia is cancer of the body's blood-forming tissues, which includes the bone marrow as well as the lymphatic system. There are several types of leukemia, and some even affect the children, however, mostly leukemia occurs in adults. According to Cancer.org, most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells. . To understand the course of treatment that the actor may have undergone, we spoke exclusively to subject matter expert Dr Rahul Bhargava, Director, Haematology, Haemato - Oncology and Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram. The doctor says the way it appears, the star must have suffered from Acute myeloid leukemia (AML) which is a cancer that starts in the bone marrow, which is the soft inner part of certain bones, where the body makes new blood cells. This often quickly moves into the blood, as well. Talking about the treatment for this particular illness, Dr Bhargava said, There is a possibility that he underwent a MUD (Match unrelated donor) transplant with reduced intensity conditioning (RIC), which basically means that he was given a lower intensity treatment, considering his age. How does MUD work?In MUD, stem cells from outside are injected in the body, and mature stem cells are targeted and removed. A person has to be in the hospital for close to 21-25 days for this procedure and then we wait and see how the body responds to the treatment. The doctor adds that clearly the treatment couldnt control his disease and he succumbed to it.

View original post here:
Rishi Kapoor succumbs to Leukemia: Here is all we know about the condition and treatment - Times of India

Read More...

Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), for the Treatment…

May 1st, 2020 9:45 pm

Company Announcement

Copenhagen, Denmark; May 01, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of the subcutaneous formulation of daratumumab, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj). The Biologics License Application (BLA) for this formulation was submitted by Genmabs licensing partner, Janssen Biotech, Inc. (Janssen) in July 2019. DARZALEX FASPRO is approved for the treatment of adult patients with multiple myeloma: in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT); in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. DARZALEX FASPRO is a fixed-dose formulation that can be administered over approximately three to five minutes, significantly less time than intravenous DARZALEX, which is given over several hours. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

The approval was based on data from two studies: the Phase III non-inferiority COLUMBA (MMY3012) study, which compared the subcutaneous formulation of daratumumab to the intravenous formulation in patients with relapsed or refractory multiple myeloma and data from the Phase II PLEIADES (MMY2040) study, which is evaluating subcutaneous daratumumab in combination with different standard multiple myeloma treatment regimens. The topline results from the COLUMBA study were announced in February 2019 and subsequently presented in oral sessions at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and the 24th European Hematology Association (EHA) Annual Congress. An update of the COLUMBA data as well as data from the PLEIADES study were presented during poster sessions at the 61st American Society of Hematology (ASH) Annual Meeting in December 2019.

The approval of the subcutaneous formulation of daratumumab, DARZALEX FASPRO, is a landmark event in the development of daratumumab. Not only is it now the first and only subcutaneous CD38 antibody approved for the treatment of multiple myeloma, the subcutaneous administration of DARZALEX FASPRO considerably reduces treatment burden, as the fixed-dose injection is administered in approximately three to five minutes, offering patients a more convenient treatment experience. As seen in the pivotal study supporting the approval, this reduction in infusion time from hours to minutes led to higher satisfaction levels for patients and in addition, infusion-related reactions were both mild and significantly reduced with this formulation of daratumumab. We are very much looking forward to the launch of DARZALEX FASPRO in the U.S. and the potential for positive impact it will have on the lives of the patients receiving the drug, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

About the COLUMBA (MMY3012) studyThe Phase III trial (NCT03277105) is a randomized, open-label, parallel assignment study that included 522 adults diagnosed with relapsed and refractory multiple myeloma. Patients were randomized to receive either: subcutaneous (SC) daratumumab, as 1,800 mg daratumumab with rHuPH20 2,000 U/mL once weekly in Cycle 1 and 2, every two weeks in Cycles 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study; or 16 mg/kg IV daratumumab once weekly in Cycle 1 and 2, every two weeks in Cycles 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The co-primary endpoints of the study are overall response rate and Maximum trough concentration of daratumumab (Ctrough; defined as the serum pre-dose concentration of daratumumab on Cycle 3 Day 1).

About the PLEIADES (MMY2040) studyThe Phase II trial (NCT03412565) is a non-randomized, open-label, parallel assignment study that includes 265 adults either newly diagnosed or with relapsed or refractory multiple myeloma. Patients with newly diagnosed multiple myeloma are being treated with 1,800 mg SC daratumumab in combination with either bortezomib, lenalidomide and dexamethasone (D-VRd) or bortezomib, melphalan and prednisone (D-VMP). Patients with relapsed or refractory multiple myeloma are being treated with 1,800 mg SC daratumumab plus lenalidomide and dexamethasone (D-Rd). An additional cohort of patients with relapsed and refractory multiple myeloma treated with daratumumab plus carfilzomib and dexamethasone (D-Kd) was subsequently added to the study. The primary endpoint for the D-VMP, D-Kd and D-Rd cohorts is overall response rate. The primary endpoint for the D-VRd cohort is very good partial response or better rate.

About DARZALEX (daratumumab) DARZALEX (daratumumab) intravenous infusion is indicated for the treatment of adult patients in the United States: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant (ASCT); in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for ASCT; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for ASCT; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma. DARZALEX intravenous infusion is indicated for the treatment of adult patients in Europe: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for ASCT; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for ASCT; in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for ASCT; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy2. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S. In Japan, DARZALEX intravenous infusion is approved for the treatment of adult patients: in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for ASCT; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for ASCT; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma. DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan. For more information, visit http://www.DARZALEX.com.

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, is approved in the United States for the treatment of adult patients with multiple myeloma: in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. DARZALEX FASPRO is the first subcutaneous CD38-directed antibody approved in the U.S. for the treatment of multiple myeloma.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a persons own immune system to attack the cancer cells, resul cvfting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).1,2,3,4,5,6

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and refractory and frontline multiple myeloma settings. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis and T-cell acute lymphocytic leukemia (ALL). Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of three approved antibodies: DARZALEX (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Arzerra (ofatumumab, under agreement with Novartis AG), for the treatment of certain chronic lymphocytic leukemia indications in the U.S., Japan and certain other territories and TEPEZZA (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development by Novartis for the treatment of relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody platform for generation of bispecific antibodies, the HexaBody platform, which creates effector function enhanced antibodies, the HexElect platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Contact: Marisol Peron, Corporate Vice President, Communications & Investor Relations T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations: Andrew Carlsen, Senior Director, Investor RelationsT: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmabs most recent financial reports, which are available on http://www.genmab.com and the risk factors included in Genmabs most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at http://www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; DuoBody in combination with the DuoBody logo; HexaBody; HexaBody in combination with the HexaBody logo; DuoHexaBody; HexElect; and UniBody. Arzerra is a trademark of Novartis AG or its affiliates. DARZALEX and DARZALEX FASPRO are trademarks of Janssen Pharmaceutica NV. TEPEZZA is a trademark of Horizon Therapeutics plc.

1 DARZALEX Prescribing information, April 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761036s027lbl.pdf Last accessed April 20202 DARZALEX Summary of Product Characteristics, available at https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex Last accessed October 20193 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.4 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.5 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.6 Jansen, JH et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking.Blood. 2012; 120(21): abstract 2974

Company Announcement no. 19CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122

Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark

See the original post here:
Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), for the Treatment...

Read More...

Could Innate Immunology Save Us From the Coronavirus? – The New York Times

May 1st, 2020 9:45 pm

As the world waits for a coronavirus vaccine, tens of thousands of people could die. But some scientists believe a vaccine might already exist.

Surprising new research in a niche area of immunology suggests that certain live vaccines that have been around for decades could, possibly, protect against the coronavirus. The theory is that these vaccines could make people less likely to experience serious symptoms or even any symptoms if they catch it.

At more than 25 universities and clinical centers around the world, researchers have begun clinical trials, primarily in health care workers, to test whether a live tuberculosis vaccine that has been in use for 99 years called the bacillus Calmette-Gurin, or B.C.G., vaccine, could reduce the risks associated with the coronavirus.

Another small but esteemed group of scientists is raising money to test the potential protective effects of a 60-year-old live polio vaccine called O.P.V.

Its counterintuitive to think that old vaccines created to fight very different pathogens could defend against the coronavirus. The idea is controversial in part because it challenges the dogma about how vaccines work.

But scientists understanding of an arm of immunology known as innate immunity has shifted in recent years. A growing body of research suggests that live vaccines, which are made from living but attenuated pathogens (as opposed to inactivated vaccines, which use dead pathogens) provide broad protection against infections in ways that no one anticipated.

We cant be certain as to what the outcome will be, but I suspect itll have an effect on the coronavirus, said Jeffrey Cirillo, a microbiologist and immunologist at Texas A&M University who is leading one of the B.C.G. trials. Question is, how big will it be?

Scientists stress that these vaccines will not be a panacea. They might make symptoms milder, but they probably wont eliminate them. And the protection, if it occurs, would most likely last only a few years.

Still, these could be a first step, said Dr. Mihai Netea, an immunologist at Radboud University in the Netherlands who is leading another one of the trials. They can be the bridge until you have the time to develop a specific vaccine.

The first evidence to suggest that live vaccines could be broadly protective trickled in nearly a century ago, but no one knew what to make of it. In 1927, soon after B.C.G. was rolled out, Carl Naslund of the Swedish Tuberculosis Society observed that children vaccinated with the live tuberculosis vaccine were three times less likely to die of any cause compared with kids who werent.

One is tempted to explain this very low mortality among vaccinated children by the idea that B.C.G. vaccine provokes a nonspecific immunity, he wrote in 1932.

Then, in clinical trials conducted in the 1940s and 50s in the United States and Britain, researchers found that B.C.G. reduced nonaccidental deaths from causes other than tuberculosis by an average of 25 percent.

Also in the 1950s, Russian researchers, including Marina Voroshilova of the Academy of Medical Science in Moscow, noticed that people who had been given the live polio vaccine, compared with people who hadnt, were far less likely to fall ill with the seasonal flu and other respiratory infections. She and other scientists undertook a clinical trial involving 320,000 Russians to more carefully test these mysterious effects.

They found that among individuals who had received the live polio vaccine, the incidence of seasonal influenza was reduced by 75 percent, said Konstantin Chumakov, Voroshilovas son, who is now an associate director for research in the U.S. Food and Drug Administrations Office of Vaccines Research and Review.

Recent studies have produced similar findings. In a 2016 review of 68 papers commissioned by the World Health Organization, a team of researchers concluded that B.C.G., along with other live vaccines, reduce overall mortality by more than would be expected through their effects on the diseases they prevent.

The W.H.O. has long been skeptical about these nonspecific effects, in part because much of the research on them has involved observational studies that dont establish cause and effect. But in a recent report incorporating newer results from some clinical trials, the organization described nonspecific vaccine effects as plausible and common.

Dr. Stanley Plotkin, a vaccinologist and emeritus professor at the University of Pennsylvania who developed the rubella vaccine but has no involvement in the current research, agreed. Vaccines can affect the immune system beyond the response to the specific pathogen, he said.

Peter Aaby, a Danish anthropologist who has spent 40 years studying the nonspecific effects of vaccines in Guinea-Bissau, in West Africa, and whose findings have been criticized as implausible, is hopeful that these trials will be a tipping point for research in the field. Its kind of a golden moment in terms of actually having this taken seriously, he said.

The possibility that vaccines could have nonspecific effects is brow-furrowing in part because scientists have long believed that vaccines work by stimulating the bodys highly specific adaptive immune system.

After receiving a vaccine against, say, polio, a persons body creates an army of polio-specific antibodies that recognize and attack the virus before it has a chance to take hold. Antibodies against polio cant fight off infections caused by other pathogens, though so, based on this framework, polio vaccines should not be able to reduce the risk associated with other viruses, such as the coronavirus.

But over the past decade, immunologists have discovered that live vaccines also stimulate the innate immune system, which is less specific but much faster. They have found that the innate immune system can be trained by live vaccines to better fight off various kinds of pathogens.

For instance, in a 2018 study, Dr. Netea and his colleagues vaccinated volunteers with either B.C.G. or a placebo and then infected them all with a harmless version of the yellow fever virus. Those who had been given B.C.G. were better able to fight off yellow fever.

Research by Dr. Netea and others shows that live vaccines train the bodys immune system by initiating changes in some stem cells. Among other things, the vaccines initiate the creation of tiny marks that help cells turn on genes involved in immune protection against multiple pathogens.

This area of innate immunity is one of the hottest areas in fundamental immunology today, said Dr. Robert Gallo, the director of the Institute of Human Virology at the University of Maryland School of Medicine and co-founder of the Global Virus Network, a coalition of virologists from more than 30 countries. In the 1980s, Dr. Gallo helped to identify H.I.V. as the cause of AIDS.

Dr. Gallo is leading the charge to test the O.P.V. live polio vaccine as a treatment for coronavirus. He and his colleagues hope to start a clinical trial on health care workers in New York City and Maryland within six weeks.

O.P.V. is routinely used in 143 countries, but no longer in the United States. An inactivated polio vaccine was reintroduced here in 1997, in part because one out of every 2.7 million people who receive the live vaccine can actually develop polio from it.

But O.P.V. does not pose this risk to Americans who have received a polio vaccine in the past. We believe this is very, very, very safe, Dr. Gallo said. Its also inexpensive at 12 cents a dose, and is administered orally, so it doesnt require needles.

Some scientists have raised concerns over whether these vaccines could increase the risk for cytokine storms deadly inflammatory reactions that have been observed in some people weeks after they have been infected with the coronavirus. Dr. Netea and others said that they were taking these concerns seriously but did not anticipate problems. For one thing, the vaccines will be given only to healthy people not to people who are already infected.

Also, B.C.G. may actually be able to ramp up the bodys initial immune response in ways that reduce the amount of virus in the body, such that an inflammatory response never occurs. It may lead to less infection to start with, said Dr. Moshe Arditi, the director of the Infectious and Immunological Diseases Research Center at Cedars-Sinai Medical Center in Los Angeles, who is leading one of the trial arms.

The science on this is still early days. Several pre-prints scientific papers that have not yet been peer-reviewed published over the past few months support the idea that B.C.G. could protect against the coronavirus. They have reported, for instance, that death rates are lower in countries that routinely vaccinate children with B.C.G. But these studies can be fraught with bias and difficult to interpret; its impossible to know whether the vaccinations, or something else, provided the protection.

Such studies are at the very bottom of the evidence hierarchy, said Dr. Christine Stabell Benn, who is raising funds for a Danish B.C.G trial. She added that the protective effects of a dose of B.C.G given to adults decades ago, when they were infants, may well differ from the protective effects the vaccine could provide when given to adults during an outbreak.

In the end, said Dr. Netea, only the clinical trials will give the answer.

Thankfully, that answer will come very soon. Initial results from the trials that are underway may be available within a few months. If these researchers are right, these old vaccines could buy us time and save thousands of lives while we work to develop a new one.

Melinda Wenner Moyer is a science and health writer and the author of a forthcoming book on raising children.

See the article here:
Could Innate Immunology Save Us From the Coronavirus? - The New York Times

Read More...

5 Powerful Orlando Women: 2020 Women Who Move The City – Orlando Magazine

May 1st, 2020 9:45 pm

MARNIE FORESTIERICEO | Young Innovators Academy and Childcare Network

Marnie Forestieri had been trying to solve one problem for years: to improve the salaries of early-childhood teachers. A former childcare franchisee and franchisor, she was unable to find the solution within the franchise modela business model that takes up to 10% of the total revenue of an operator not leaving room for a pay increase or career advancement opportunities. As an educator, she was concerned about the high teacher turnover rate of the industry and was aware of the importance of providing young children with a stable and trained workforce during the most critical years of brain development.

Thats when she decided to start looking outside the industry for a solution. Forestieris new brainchild, Young Innovators Academy, is an alternative business model that aims to compete with established childcare franchises by offering future childcare entrepreneurs a lower market entry and simple licensing contracts. Her platform streamlines all the services needed in childcare operations so new providers can compete with existing childcare brands. But its not just about operations: the real differentiator of Young Innovators is their curriculumone that aims to give children the Innovation Advantage. Through a preschool curriculum inspired by the design-thinking process from the Stanford University and Harvard Universitys maker centered learning, the company hopes to prepare children for the careers of the future.

The team was right on target to roll out the first childcare centers powered by their technology platform this year when Covid-19 happened. To support their parents during the crisis, the Young Innovators team decided to take on a new mission. Forestieri drew from her previous experiences as a TV producer to turn the companys lab school into a professional TV Studio featuring a daily circle time on YouTube and weekly lesson plans for parents. During the process, her staff transition from teaching positions to on-camera, curriculum development, and social media roles. Forestieri believes that infusing the maker mindset at a young age allows children to become agents of change and that teachers practicing the maker mindset is a precursor to teaching Innovation principles.

163 E. Morse Blvd. | Suite 230 | Winter Park, FL 32789 | Phone: 407-988-0230 | younginnovatorsacademy.com

Elisha Gonzlez has been a positive agent for change throughout her professional career, which has spanned more than 25 years. Ive found that a willingness to embrace change is critical for success. Change is a constant, no matter the industry, success depends on how you adapt.

Gonzlez is a connector and relationship builder who has long been recognized for her leadership, business acumen and commitment to community. Her background includes working for the Orange County Public School system, the U.S. Senate, Valencia College, Duke Energy and now, Fairwinds Credit Union as Vice President of Community Relations and Government Affairs. She also serves as Executive Director of the nonprofit Fairwinds Foundation, where she leads the effort to bolster organizations that advocate financial literacy and volunteerism by working with Fairwinds crew members in community outreach.

Gonzlez has been instrumental in the new, unified vision for the FAIRWINDS Foundation that wants to help the communities they serve be debt free. We want our community to save more, eliminate debt, build wealth so that they experience financial freedom and have the opportunity to live generously.

She is enjoying her latest career transition to the financial sector. Some competencies are not industry-specific, says Gonzlez. No matter what business youre in, people are always at the heart of any industry. Your ability and willingness to develop a deep understanding of customers, co-workers and the business will determine your level of effectiveness within the organization. As someone who enjoys connecting with people, Im grateful that my career has been characterized by creating meaningful connections on behalf of the organizations I represent.

Gonzlez has been recognized for her extensive community work and leadership on the boards of numerous nonprofits that revolve around inclusion, diversity and education. She has a deep commitment to the organizations she has championed, including Heart of Florida United Way, Project Opioid, the Holocaust Memorial Resource and Education Center, Orlando Economic Partnership, the Hispanic Heritage Scholarship Fund of Metro Orlando, and CareerSource Florida workforces initiatives. Im passionate about breaking down inequality, discrimination and barriers to the economic and social prosperity of our community.

135 W. Central Blvd. | Orlando, FL 32801 | Phone: 407-277-5045 | FAIRWINDS.ORG/Foundation

After graduating college with a degree in business and marketing, Caryn Green served as a Guardian ad Litem, a decision that launched her 20+ year law career helping families through difficult transitions. I was asked to testify at trial on one of my files that involved a potential termination of a parents right to see her child, she recalls. I was frustrated by how ill-prepared the lawyers were, especially with what was at stake. The combination of gathering evidence and properly presenting it to a court immediately appealed to me. On my way home from court, I stopped by the bookstore and bought an LSAT study guide and immediately signed up to take the test. Caryn brings a unique perspective in her approach to law and family life. Practicing law has definitely taught me to compromise. Compromise, respect and support are essential for a healthy, happy family. She works to resolve family disputes as painlessly as possible, especially for the sake of children involved. Her focus on family helps Caryn maintain balance in her life, and she cites her role as a mother of two well adjusted, intelligent, kind and thoughtful daughters as her greatest accomplishment. She encourages her daughters to follow their dreams. One of my daughters has expressed a desire to be a lawyer, and the other has definitely crossed it off her list. Caryn was inspired by her law professors and hopes to someday teach at a law school. Caryn continues to serve the people of Orlando, which she describes as the best city in Florida with wonderful neighborhoods and a vibrant philanthropic community. After one of her daughters was diagnosed with Type 1 diabetes more than 14 years ago, Caryn launched a gala to raise money for the Juvenile Diabetes Research Foundation. In 2018, our Orlando community rose to the occasion and helped us set a record breaking year, raising almost $1 million in one night, she recalls.

1000 Legion Place | Suite 1650 | Orlando, FL 32801 | Phone: 407-403-5558 | GreenFamilyLaw.net

The tragic death of a little boy in 1992 could have been simply that: a tragic death. Instead, the short life of that little boy inspired Margaret Guedes to turn tragedy into a lifelong mission and keep the memory and legacy of her son, John, alive by helping other children diagnosed with cancer. Kids Beating Cancer is dedicated to ensuring every child who needs a bone marrow or stem cell transplant has access to this life-saving treatment. Margarets journey started when she could not find a local transplant facility. She had to displace her family and move to Seattle so that her son could get a much-needed transplant. John lived for four years before succumbing to his disease. Margaret then vowed to make sure no other mother or child had to experience what she and her son went through by bringing a state-of-the art transplant center to Central Florida. Margaret exhibits a mothers determination to fight for every child who needs a transplant to receive the best care in the best facility. She also works to ensure every family receives support programs to make each day a little more bearable as they navigate the long journey to a cure. Turning personal tragedy into triumph has been the core value that has driven Margaret to overcome years of barriers, ultimately leading to the opening of the Kids Beating Cancer Pediatric Transplant Center. She built Kids Beating Cancer with all that in mind, knowing how devastating it is to have a family member diagnosed with cancer. The support and engagement of the local community, corporations, private foundations and individual donors has made Kids Beating Cancer what it is today. Through Margarets tenacity and leadership, Kids Beating Cancer has become a nationally recognized nonprofit, touching the lives of more than 10,000 children. Children have received millions of dollars in life-saving treatments at the Kids Beating Cancer Pediatric Transplant Center, which brings the latest treatments to each childs bedside. Since 1992, Margaret has put more than $22 million back into the community to help every child with cancer or leukemia have the best hope for a cure. She has also started The Science is the Cure Research Grant to fund the cure through innovative and novel research by developing new treatments for blood cancers and cellular therapies.

228 E. Winter Park St. | Orlando, FL 32804 | Phone: 407-894-2888 | kidsbeatingcancer.com

Kelly Price, an entrepreneurial icon and one of Floridas preeminent brokers, has made herself into a household name in the Orlando real estate industry. Having lived in Winter Park since she was twelve years old, Kelly is a proud Winter Park High School Wildcat, a University of Florida Gator, and an MBA graduate of Rollins Crummer School of Business. Over the years, she developed an astute and competitive eye for real estate which has been fostered by passion for her community.

When she launched her company in 2002, the mantra that she built it upon was Integrity, loyalty, and unwavering enthusiasm. Her main focus was to guarantee her clients a new level of exceptional professionalism unsurpassed by any other in the real estate industry. Backed by a group of dynamic agents, Kelly Price & Company offers steadfast commitment to clients, swift communication, and positivity, all blending together to provide award-winning service.

While quarantines, stay-home orders, and social distancing have become todays norm as the world attempts to flatten the curve, these changes in behavior have not reduced the amount of work getting done. Kelly Price & Company remains a leader in the community thanks to its top notch agents and use of technology. Although they may not be able to interact with their clients in person, the agents continue to creatively find alternative ways to offer home buying and selling options. The company will continue to proactively follow guidelines from the CDC and take preventive measures on an ongoing basis to maintain a safe environment for all involved. With the support of Kellys personal family and her ever-growing family at Kelly Price & Company, nothing can stop her!

Kelly will always claim Winter Park as her home and is dedicated to limitlessly serving not just her immediate community, but also Central Florida as a whole. She is a charismatic ambassador and local advocate, proudly representing Central Floridas most distinguished homes for more than 30 years. Although the use of technology has helped the company continue to move business forward, she cant wait for things to get back to normal and have face-to-face interactions with her clients who become friends, and friends who become family.

243 W. Park Avenue | Winter Park, FL 32789 | Phone: 407-645-4321 | KellyPriceAndCompany.com

Go here to see the original:
5 Powerful Orlando Women: 2020 Women Who Move The City - Orlando Magazine

Read More...

Coronavirus Update: Baptist Hospital Patient Credits Stem Cell Treatment With Saving Her Life – CBS Miami

May 1st, 2020 9:44 pm

MIAMI (CBSMiami) The FDA gave Baptist Health approval to test a stem cell treatment on COVID-19 patients and so far its come back with positive results.

The treatment has proven successful with three patients.

One of those patients, Ruth Ramirez says it saved her life.

Ramirez was discharged from the hospital on Friday afternoon.

They saved my life. They definitely saved my life, said Ramirez.

Ramirez recently received stem cells from an umbilical cord known as mesenchymal cells.

Mesenchymal stem cells have the ability to reduce cytokine levels, said doctor Guenther Koehne.

Baptist Hospital says patients like Ramirez showed a reduction of their oxygen requirement from 100% to less than 50% within days of the infusion, accompanied by a significant reduction in levels of various key circulating inflammatory markers.

I couldnt breathe. I had a fever a headache I was nauseous, said Ramirez.

Ruth, an employee of the Miami Cancer Institute, tested positive for COVID-19 back on April 7th. She was admitted to the ICU and ended up on a ventilator fighting for her life.

Knowing she may lose consciousness she gave her sister power of attorney. That is when doctors Koehne and Javier Perez Fernandez approached the family about this FDA approved experimental therapy.

Im a person who jumps. I jump with hope with the best outcome there is on the other side. I think she took that into consideration with my characteristic and said Ruth would probably do this.

According to friends, Ruth was in ICU for three weeks, on a ventilator, and unable to breathe on her own.

All that time, she was away from her two small kids. That was several days ago.

On Friday, she was discharged.

To be here in this room, alone, and not being able to hold them. It was hard you know its hard.

As soon as they told me that I was going home I was like what?? And that I tested negative again I was like wait!! That changed my mood completely

Still fuzzy on the timeline, Ruth says shes unsure where along the way she received the treatment but is thankful for the doctors and wants others to know there is hope.

You know I hear the bells here all the time the eye of the tiger thats the song that you walk out of when you come out with coronavirus. Its such a pleasure hearing it all the time now. More than I heard it yesterday.

Not only did the doctors step up, but so did her co-workers who set up this Ruthie-strong go fund me page to help with bills and expenses.

They also helped take care of her family.

They would send food to them. Groceries. My kids were taken care of my sister was taken care of. She didnt have to leave from the house.

Theyre just amazing.

The University of Miami is also working on a clinical trial using mesenchymal cells which we reported on in April.

Click here if you would like to donate to her GoFundMe page.

RELATED:Drive-Through Testing LocationsTrack The Spread Of The Coronavirus In Real TimeTips To Protect Your Vehicle While It Sits Unused During Coronavirus Stay-At-Home Ordercoronavirus

See the article here:
Coronavirus Update: Baptist Hospital Patient Credits Stem Cell Treatment With Saving Her Life - CBS Miami

Read More...

Page 571«..1020..570571572573..580590..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick